STRATEGIC NEWS WATCH — September 8, 2026
|
Novartis’s del-desiran missed the primary endpoint of the Phase 3 HARBOR trial in myotonic dystrophy type 1 — video hand opening time, a novel measure of hand myotonia — sending shares down about 12% pre-market and delivering the first pivotal test, and first failure, of the platform thesis behind its $12 billion Avidity acquisition. Today’s top developments:
|
What to Watch
- HARBOR’s secondary data and the regulatory path — Novartis reports clinical activity in secondary and exploratory endpoints without quantifying any of it, and has named neither a congress nor a date for full results. Those numbers, and the health-authority discussions that follow, decide whether del-desiran has a path forward or the $12 billion case now rests on the Duchenne and FSHD programs.
Unlock the Rare Disease calendar → - Etcamah’s confirmatory survival — This is an accelerated approval and overall survival from SERENA-6 is still immature, with a confidence interval that crosses 1 (HR 0.87; 95% CI 0.57–1.30). Conversion to full approval turns on the OS readout, and the FDA has grown less tolerant of immature survival data in this setting than it once was.
- Arlo-cel’s actual numbers — QUINTESSENTIAL met its endpoint with no figures released and no meeting named. The response and complete-response rates against Talvey’s 72% ORR — and whether BMS files on the Phase 2 or waits for the Phase 3 due in 2028 — are what will show whether the tolerability edge becomes a commercial one.
- Two separate Pharvaris decisions — The immediate-release on-demand NDA carries a PDUFA date of April 23, 2027; the extended-release prophylaxis NDA is due to be filed in the first half of 2027. Watch them separately, because approval of one says little about the other.
- Generic-tariff implementation detail — The proposed schedule begins at 100% in August 2028 and rises to 200% in 2029, leaving nearly two years for exemptions, carve-outs and reshoring commitments to be negotiated. Essential-medicines exemptions, not the headline rate, will determine the effect on US drug supply.
This brief highlights the edition’s top stories. Read the full September 8, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.